Comparative analyses of adeno-associated viral vector serotypes 1, 2, 5, 8 and 9 in marmoset, mouse and macaque cerebral cortex  by Watakabe, Akiya et al.
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Here  we  investigated  the  transduction  characteristics  of adeno-associated  viral  vector  (AAV)  serotypes
1,  2,  5,  8 and  9 in the  marmoset  cerebral  cortex.  Using  three  constructs  that  each  has  hrGFP  under
ubiquitous  (CMV),  or neuron-speciﬁc  (CaMKII  and Synapsin  I  (SynI))  promoters,  we  investigated  (1)  the
extent of  viral  spread,  (2)  cell  type  tropism,  and  (3)  neuronal  transduction  efﬁciency  of each  serotype.
AAV2  was  clearly  distinct  from  other  serotypes  in  small  spreading  and  neuronal  tropism.  We  did  not
observe  signiﬁcant  differences  in viral  spread  among  other  serotypes.  Regarding  the  cell tropism,  AAV1,
5,  8 and  9 exhibited  mostly  glial expression  for CMV  construct.  However,  when  the  CaMKII  construct  was
tested,  cortical  neurons  were  efﬁciently  transduced  (>∼70%  in layer  3)  by  all  serotypes,  suggesting  thatiral vector
onkey
on-human primate
euron
glial expression  obscured  neuronal  expression  for  CMV  construct.  For  both  SynI  and  CaMKII  constructs,
we observed  generally  high-level  expression  in  large  pyramidal  cells  especially  in layer  5,  as  well  as
in  parvalbumin-positive  interneurons.  The  expression  from  the  CaMKII  construct  was  more  uniformly
observed  in excitatory  cells  compared  with  SynI  construct.  Injection  of the  same  viral  preparations  in
mouse  and  macaque  cortex  resulted  in essentially  the  same  result  with  some  species-speciﬁc  differences.
© 2014  The  Authors.  Published  by Elsevier  Ireland  Ltd.  This  is an  open  access  article  under  the CC. Introduction
Adeno-associated viral vectors (AAVs) have now become one of
he standard tools for gene delivery into central nervous system.
ransduction of neurons with optogenetic molecules, for example,
rovides unprecedented opportunities to manipulate neural circuit
Betley and Sternson, 2011; Fenno et al., 2011; Han, 2012). To pro-
uce recombinant AAV particles, the transcription unit of interest is
andwiched between the two inverted terminal repeat sequences
ITRs) of AAV, which is packaged with capsids provided in trans. One
haracteristic feature of AAV is that there exist a huge number of
ifferent serotypes that exhibit unique species- and tissue tropism
Rabinowitz et al., 2002; Klein et al., 2008; Wu et al., 2006). The
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capsids derived from these serotypes can be used to package the
transfer vector of AAV2 to confer unique transduction properties
and cell tropisms (Rabinowitz et al., 2002).
To date, many studies have investigated the transduction prop-
erties of AAV serotypes for the nervous system. AAV1, 2, 5, 8
and 9 have been shown to transduce neurons and glias in the
striatum, hippocampus, neocortex, substantia nigra, retina and
amygdala among others (Burger et al., 2004; Cearley and Wolfe,
2006; Taymans et al., 2007; Klein et al., 2008; Blits et al., 2010;
Hutson et al., 2012; Aschauer et al., 2013; Holehonnur et al.,
2014). Other serotypes such as AAV6, AAV7, AAV-DJ, AAVRh10, and
AAVRh43 are potentially useful but less well examined (Aschauer
et al., 2013; Cearley and Wolfe, 2006; Holehonnur et al., 2014;
Klein et al., 2008). Most of these studies were done for rodents,
but some studies focused on non-human primates (Dodiya et al.,
2010; Markakis et al., 2010; Masamizu et al., 2011; Sanchez et al.,
2011). What became clear from these analyses is that the extent of
viral spread and the cell tropism could be quite different between
serotypes depending on the target tissue and species. Therefore, it
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Table 1
Marmosets used in this study.
ID Construct Serotypes Expression
#1 CMV-hrGFP AAV1, 2 3 weeks
#2 CMV-hrGFP AAV5, 8, 9 3 weeks
#3 CMV-hrGFP AAV1, 9 6 weeks
#4 CaMKII-hrGFP AAV1, 2, 8, 9 6 weeks
SynI-hrGFP AAV1, 2, 8, 9
#5 CaMKII-hrGFP AAV1, 2, 5, 8, 9 6 weeks
#6 CaMKII-hrGFP AAV5, 9 3 weeksA. Watakabe et al. / Neurosci
s desirable to use the appropriate AAV serotypes for transduction
ccording to the needs of each experiment.
This study started from the motivation to identify the appro-
riate serotypes to transduce cortical neurons of the non-human
rimates, in particular, marmosets. Marmoset, a small New World
onkey, is a good model organism for neuroscience research
Clarke et al., 2004; Bendor and Wang, 2005; Okano et al., 2012)
nd we are interested in using it as a model to investigate the
rimate-speciﬁc architecture of the cerebral cortex (Yamamori
nd Rockland, 2006; Watakabe et al., 2012). To begin with, we
njected various AAV serotypes containing a GFP reporter under
biquitous CMV  promoter to marmoset cortex. Unexpectedly, we
bserved mainly glial expression for AAV1, 5, 8 and 9, which
ppeared to contradict past studies (Nathanson et al., 2009; Blits
t al., 2010; Masamizu et al., 2010). This led us to investigate
he transduction efﬁciency of AAV serotypes using neuron-speciﬁc
romoters such as CaMKII and SynI promoters. For comparison,
e also injected the same preparation of AAVs to mouse and
acaque cortex. We  describe and discuss the transduction prop-
rties of ﬁve AAV serotypes that emerged from a series of our
nalyses.
. Materials and methods
.1. Ethics statement
All the experiments were conducted in accordance with the
uideline of the National Institutes of Health, and the Ministry
f Education, Culture, Sports, Science and Technology (MEXT) of
apan, and were approved by the Institutional Animal Care and Use
ommittee of National Institutes of Natural Sciences. We  made all
fforts to minimize the number of animals used and their suffering.
.2. Plasmid construction
The constructs used in this study are schematically shown in
ig. 1O. The CMV-hrGFP construct (pAAV-hrGFP) was obtained from
gilent Technologies Inc. (originally obtained from Stratagene). The
MV promoter and beta-globin intron sequences were excised and
eplaced either with SynI promoter (Hioki et al., 2009) and CaMKII
romoter (CaMKII alpha 1.3: a gift from Drs. Ryosuke Matsui and Dai
atanabe, Kyoto University) to make SynI and CaMKII constructs.
.3. Viral injection
Adeno-associated viral (AAV) vectors used in this paper have
TRs of AAV2 and with capsids of serotype 1, 2, 5, 8 and 9. They
ere produced in HEK 293 cells by using a helper virus free sys-
em and puriﬁed by two times CsCl2 density gradients and titrated
y Q-PCR as described previously (Yagi et al., 2011). Our vector
itration results were consistent with those quantiﬁed in reference
o the international standard, which was recently used in a mul-
icenter collaborative study (Lock et al., 2010). Final preparations
ere dialyzed against PBS and adjusted to 0.5 × 1013 GC (genome
opies)/ml for CMV  construct and 0.4 × 1013 GC/ml for CaMKII and
ynI constructs.
Seven adult marmosets (Callithrix jacchus) of both sexes were
sed in this study (Table 1). Following an intramuscular injection
f ketamine/xylazine mixture (30 mg/kg, 1.3 mg/kg, respectively),
eep anesthesia was induced by isoﬂurane (1–2%) inhalation. The
ead of the marmoset was ﬁxed to the stereotaxic apparatus and
urgery was carried out under continuous monitoring of the heart
ate and the rectal temperature. A small hole was made in the skull
sing a dental drill. The viral vector was delivered by pressure injec-
ion using a glass micropipette attached either to a nanoliter 2000#7 CMV-hrGFP AAV1 3 weeks
CaMKII-hrGFP AAV1
injector connected to Micro4 controller (World Precision instru-
ment), or to a microinfusion pump (Harvard Apparatus). To inject
virus into the brain, the dura was punctured using a tip of 27G
needle, through which the glass pipette was  slowly lowered to the
target depth. Approximately 0.5, 0.63 or 0.63 l (for CMV, CaMKII
or SynI constructs, respectively) of the viral solutions containing
2.5 × 109 GC were injected at the rate of 0.1 or 0.125 l/min. The
pipette was held in place for 2 min  before and after the injection.
After retracting the glass micropipette, the hole was  ﬁlled with
Spongel, an absorbable gelatin sponge (Astellas Pharma Inc.) and
the head skin was  sutured. The marmosets were sacriﬁced three or
six weeks after injection.
Fourteen adult C57BL6J mice of either sex (17–28 weeks)
were anesthetized with an intraperitoneal injection of
ketamine/xylazine mixture (100 mg/kg, 10 mg/kg, respectively).
The virus injection was performed in a similar manner as described
above for marmoset. In these mice, approximately 0.5 l of the
viral solutions injected into somatosensory area (AP + 1 mm,  left
3 mm,  depth 0.5 mm).  These mice were sacriﬁced three weeks
after injection.
Eight hemispheres of four adult macaque monkeys (two male
Macaca mulatta, male and female Macaca fuscata) were used. Under
the same surgical procedure reported previously (Kinoshita et al.,
2012), the injections were made after the craniotomy at the frontal
lobe and the occipital lobe. After incision of the dura or making a
small hole on the dura with 18-gauge needle, the glass micropipette
(tip diameter 100–120 m)  was penetrated at the depth 0.4 mm
and/or 0.8–1.0 mm from the cortical surface of the occipital lobe,
at 1.0–1.5 mm  for frontal lobe or at 3.0 mm in the frontal lobe near
the central sulcus. Approximately 0.5 or 0.8 l of the viral solu-
tions, which had the same constructs and titer as those used in the
marmosets, were injected into each site at the rate of 0.1 l/min
under the control of a microinfusion pump (Eicom). The pipette
was held in place for 5 min  after the injection. After the retrac-
tion of the micropipette, the dura was sutured (if necessary) and
covered with Spongel (Astellas Pharma Inc.), and the skin was
sutured. The animals were sacriﬁced six-eight weeks after the
injections.
2.4. Immunostaining and data analyses
Animals were anesthetized with sodium pentobarbital and per-
fused transcardially with 0.9% NaCl, followed by ﬁxation with 4%
paraformaldehyde in 0.1 M phosphate buffer, pH 7.4. The ﬂuores-
cent signals of hrGFP were strong enough to be detected without
enhancement by immunodetection. For some experiments, how-
ever, we performed antibody staining using anti-hrGFP to clearly
distinguish the ﬂuorescent signals from the background autoﬂuo-
rescence. For immunoﬂuorescence, the sections were treated with
80% methanol/20% dimethyl sulfoxide solution (Dent’s solution)
for more than 30 min. After washing, the sections were blocked
with 10% fetal bovine serum, 2% bovine serum albumin, and 0.5%
Triton X-100 in TBS, pH 7.4, followed by overnight incubation
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Fig. 1. Various AAVs injected into marmoset cerebral cortex. AAV constructs containing CMV, CaMKII, and SynI promoters driving hrGFP expression were packaged in AAV1,
2,  5, 8, and 9 capsids and injected into the marmoset cerebral cortex. The low-magniﬁed images of representative sections are shown for each combination. These are merged
views  for hrGFP (green) and NeuN (red) signals. To aid visualization, the contrasts of images are adjusted. So that we can directly compare the signal intensities across
serotypes, the sections for the same promoters were immunostained simultaneously, imaged and contrast-adjusted in exactly the same conditions. These images were taken
from  marmosets ID#1 and #2 for CMV  promoter (panels A–E), ID#5 for CaMKII promoter (panels F–J) and ID#4 for SynI promoter (panels K–N). Panel O shows the schematic
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eferred to the web  version of this article.)
ith the primary antibody for hrGFP (rabbit polyclonal, 1:4000;
gilent Technology #240141), and for NeuN (mouse monoclonal,
illipore, MAb377) at 4 ◦C. After incubation with ﬂuorophore-
onjugated secondary antibodies, the sections were counterstained
ith Hoechst 33342 (1:2000; Molecular Probes). The ﬂuorescent
mages were captured by Olympus DP71 digital camera attached
o BX51 microscope (Olympus). The confocal images were taken
y Nikon confocal laser microscope system A1. Maximum intensity
rojection images for the confocal data were created by NIS-
lements imaging software (Nikon). All the images were processed
y Adobe Photoshop for proper contrast for presentation.
For measurement of viral spread, a circle was  drawn to
over the center of the transduction and the radius was mea-
ured. Viral spread in layers 2 and 5 was ignored, because itxis. (For interpretation of the references to color in this ﬁgure legend, the reader is
unpredictably goes beyond the circle. In counting the neuronal
transduction efﬁciency of CaMKII-construct, a single optical sec-
tion of hrGFP/NeuN/Hoechst stained section was captured using
40× objective lens. A ROI with 150 m × 150 m size was selected
from the image. We  ﬁrst identiﬁed NeuN positive cell bodies. To
avoid the interference of strong ﬂuorescence that is not directly
on the optical section, we counted only the NeuN-positive cells
with clear nuclear signals as positive. As to the hrGFP signals,
most of the imaged ﬁeld was ﬁlled with green signals after
adjusting the contrast, and it was  often difﬁcult to distinguish
the cell bodies from the surrounding tissue only by the green
ﬂuorescence. In such cases, we  counted the cells as positive,
because the transgene-negative cells can be differentiated by lack of
ﬂuorescence.
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Fig. 2. Estimation of viral spread for various serotypes. (A–D) The extent of viral spread was measured using a circle. In determining this circle, we ignored the widespread
distributions in layers 2 and 5 and set the radius to cover layer 3 expression. The examples of measurement shown in panels A–D indicate that the infection occurred along
the  cortical column and not along the needle track (white dotted line in panel A). The magniﬁcation is the same for panels A–D. (E) The red, green and blue plots represent
the  radius of viral spread for CMV, CaMKII and SynI promoters, respectively. Each plot represents independent injections. The plots indicated by a–d represent the values
for  the white circles shown in panels A–D. *When the results of different promoters were mixed, the statistically signiﬁcant difference was observed only for AAV2 being
smaller than other cell types (p < 0.001 between AAV1/5/9 and AAV2 and p < 0.05 between AAV8 and AAV2, Ryan’s method). (F and G) An example of viral spread in layers
2  and 5 beyond spherical diffusion. Panel F shows hrGFP signals of AAV1/CaMKII-hrGFP injection, while panel G shows a merge with NeuN (red). The arrow indicates viral
infection along the blood vessel. (H and I) The hrGFP and hrGFP-NeuN merged views of a section peripheral to the injection center. This section was approximately 1 mm
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2ateral from the section shown in panels F and G. The white dotted boxes are magniﬁ
rGFP-NeuN merged views of the white dotted squares in panels H and I. Note high 
f  the references to color in this ﬁgure legend, the reader is referred to the web ver
. Results
.1. Marmoset cortical neurons are efﬁciently transduced by AAV
erotypes 1, 2, 5, 8 and 9
The speciﬁc aim of the current study is to clarify how vari-
us AAV serotypes transduce the neurons of the cerebral cortex
f marmosets, mice and macaques. We  used three different pro-
oters to drive hrGFP expression, namely, CMV, CaMKII and SynI
romoter (Fig. 1O). CMV  promoter is ubiquitous, but in the context
f AAV construct, the cell-type tropism depends on the serotypes
f the capsid (Aschauer et al., 2013). CaMKII and SynI promoters
re both neuron-speciﬁc. A previous study suggested preferential
xpression in excitatory and inhibitory neurons for these promot-
rs, respectively, when packaged in AAV1 capsids (Nathanson et al.,
009).panels J and K. The magniﬁcation is the same for panels F–I. (J and K) The hrGFP and
nse expression in layer 2 as well as sparse expression in layer 5. (For interpretation
f this article.)
Fig. 1 shows the hrGFP expression from these three constructs
packaged in AAV1, 2, 5, 8 and 9 in the marmoset cortex. As this
ﬁgure shows, all the AAV vectors we  tested exhibited efﬁcient
transduction of cortical cells. At this low magniﬁcation, the differ-
ential property of each injection was manifested in three aspects.
First, there existed considerable differences in the extent of viral
spread. On ﬁrst look, the transduced area of AAV2 was smaller than
other serotypes. Second, the overall signal intensities were variable.
This was  most conspicuous for AAV5/CaMKII-hrGFP: although viral
spread was as efﬁcient as AAV8 and 9 (Fig. 1I and J), the expres-
sion level per cell was much lower for AAV5 (Fig. 1H). Finally, the
distribution of hrGFP signals was not uniform and exhibited char-
acteristic patterns for each promoter. For example, we observed
intense cell body signals that span all layers for CMV  promoter
(Fig. 1A–E), while more diffuse uniform labeling with weak layer
4 was  observed for CaMKII promoter (Fig. 1F–J). On the other hand,
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Fig. 3. Glial and neuronal expression of transgene from AAV serotypes. Marmoset cortical sections were immunostained with anti-hrGFP (green) and anti-NeuN antibody
(red)  to differentiate neuronal and glial transduction. A single optical section of confocal microscopy images are shown in each panel. These images were taken from layer
5.  (A–E) Merged views for hrGFP (green) and NeuN (red) signals of AAV1, 2, 5, 8 and 9 coding CMV-hrGFP. (A′–E′) Only hrGFP signals are shown for the same images as A–E.
The  arrowheads indicate neurons. The arrows indicate hrGFP-positive cells with apparently no NeuN signals. Among these, the arrows with stars were actually considered
to  be neurons (see panels K–M). (F–J) Merged views for hrGFP (green) and NeuN (red) signals of AAV1, 2, 5, 8 and 9 coding CaMKII-hrGFP. The dotted rectangle in panels F
and  F′ are magniﬁed in panels N–Q. (K) The cells shown by the arrow in panel A was magniﬁed. This is a typical example of a glia apposed to a neuron. (L and L′) The cell
shown  by the arrow with a star in panels D and D′ was  magniﬁed. This cell has a neuronal morphology and weak NeuN signal. (M and M′) The cell shown by the arrow with a
star  in panels E and E′ was  magniﬁed. This cell also has a neuronal morphology and weak NeuN signal. (N–O) Magniﬁed views of dotted rectangle in panels F and F′ . There is
only  one cell that is obviously positive for hrGFP. Among other cells that are positive for NeuN, the one indicated by the arrow clearly lacks hrGFP signal (see panel Q) and is
considered to be negative for hrGFP (shown by dotted circle in panels O and P). We consider other three NeuN positive cells to be also positive for hrGFP (shown by circle). (R)
The  ratio of hrGFP-positive cells among the NeuN-positive cells in layer 3 (average: bar standard deviation; n = 7 for AAV1, n = 4 for AAV2 and 5, n = 6 for AAV8 and n = 10 for
AAV9).  See materials and methods for more detail. (For interpretation of the references to color in this ﬁgure legend, the reader is referred to the web version of this article.)
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Fig. 4. Toxicity of AAV transduction for CMV-promoter construct. The toxicity of AAV transduction was monitored by reduction of NeuN signals and inﬁltration of glia cells.
(A  and B) AAV1 or AAV9/CMV-hrGFP construct was injected into the marmoset cortex and examined for transgene expression (green) after 3 weeks (marmoset #1 and 2).
At  this magniﬁcation, we  did not observe substantial changes in the level of NeuN (red), although at higher magniﬁcation, the strong hrGFP-positive cells tended to show
lower  level of NeuN (e.g., Fig. 3L and M).  (C and D) AAV1 or AAV9/CMV-hrGFP construct was  injected into the marmoset cortex and examined for transgene expression
after  6 weeks (marmoset #3). In this example, we observed residual expression of hrGFP in the glia cells with loss of NeuN-positive neurons (see panels C′ and D′). In
panels  C′′ and D′′ , the inﬁltration of glia cells were observed by strong and dense nuclear staining by Hoechst33342. (E and F) AAV1 or AAV9/CaMKII-hrGFP construct was
injected into the marmoset cortex and examined for transgene expression after 6 weeks (marmoset #4). Some glial inﬁltration was observed for AAV9 (see panel F′′). (G
and  H) AAV1 or AAV9/SynI-hrGFP construct was injected into the marmoset cortex and examined for transgene expression after 6 weeks (marmoset #4). (I) A magniﬁed
view  of AAV1/CaMKII-hrGFP construct showing no effect of hrGFP expression (green) on the level of NeuN (red). (J) A magniﬁed view of AAV1/SynI-hrGFP construct. (For
interpretation of the references to color in this ﬁgure legend, the reader is referred to the web  version of this article.)
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Fig. 5. Comparison of CaMKII and SynI construct. (A) An overview of a marmoset brain (#4) that received AAV/CaMKII-hrGFP on the left hemisphere and AAV/SynI-hrGFP
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5n  the right hemisphere. The number indicates the serotypes injected. (B–E) Comp
uorescent images were taken in the same conditions using a 10× objective, using
eakly  stained cells are more numerous in CaMKII construct than SynI construct.
ynI promoter showed weak diffuse staining with strong cell body
ignals in layers 3 and 5 (Fig. 1K–N). Such patterns are considered
o arise as a combined result of differential cell tropism of each
erotype and the cell type speciﬁcity of the promoter activity.
With this picture in mind, we analyzed the differential behavior
f AAV serotypes in (1) extent of viral spread, and (2) cell type speci-
city and transduction efﬁciency of each AAV vector in more detail.
n addition, we describe our data on the cell toxicity and cell type
peciﬁcity of CaMKII promoter in comparison with CMV  and SynI
romoter. We also compared our data on marmoset cortex with
he results in mouse and macaque monkeys to aid comparison of
ast studies.
.2. Spreading proﬁles of various AAV serotypes in the marmoset
erebral cortex
The spread of AAV particles for different serotypes were esti-
ated on the assumption that the viral spread is affected by the
apsids but not by promoters. Since the diffusion of the viral parti-
les from the injection point is expected to be spherical, we used a
ircle to determine the extent of viral spread (Fig. 2A–D). In practice,
e observed two patterns of non-spherical transduction. In most
ases, the transduction occurred in a columnar fashion beyond the
imit of spherical diffusion. Such spread likely reﬂects the columnar
rchitecture of the cortex and not caused by spread along the needle
rack, because the infection in some cases occurred oblique to the
eedle track (white dotted line in Fig. 2A). Secondly, we sometimes
ncountered very widespread transduction to occur in layers 2 and
. Fig. 2D and F–I show typical cases of widespread transduction. of unstained sections for CaMKII and SynI constructs in AAV1 and 9 capsids. These
scent microscope. (F–I) The dotted boxes in panels B–E were magniﬁed. Note that
The layer 2 transduction in such cases can spread as far as several
millimeters. This is seen in transverse section in Fig. 2F and G, as
well as in layer2/5 speciﬁc distribution of hrGFP-positive cells in the
peripheral sections (Fig. 2H–K). As shown in magniﬁed views, the
infection in layer 2 was  quite dense even in the peripheral region,
whereas infection in layer 5 mainly occurred sparsely in large pyra-
midal cells (Fig. 2J and K). This type of spread is qualitatively distinct
from the columnar spread and was ignored in determining the cir-
cle. We set the radius to cover layer 3 expression (see Fig. 2A–D as
examples). We also ignored a sporadic infection that seems to have
occurred along the blood vessel (see the arrow in Fig. 2F).
Fig. 2E shows the summary of all the injection data. ANOVA
showed that the distribution of AAV2 is statistically different
from other serotypes (p < 0.001). AAV1, 5 and 9 spread as wide
as 1.2 ± 0.2, 1.3 ± 0.3, 1.2 ± 0.4 mm (means ± SD), respectively,
whereas the distribution of AAV2 was  0.7 ± 0.2 mm.  We  could not
observe statistical differences between AAV1, 5, 8 and 9.
3.3. Efﬁciency of neuronal transduction by AAV serotypes
We  next examined the cell type preference and transduc-
tion efﬁciency of various AAV serotypes by counterstaining with
NeuN antibody for neuronal identiﬁcation. Confocal microscopic
observation at high magniﬁcation revealed that the densities
of hrGFP-positive cells were unexpectedly very low for CMV-
hrGFP construct, compared with those of NeuN positive neurons
(Fig. 3A–E). For AAV2, the obviously strong signals were sparse but
they were mostly observed in neurons (Fig. 3B). For other serotypes,
most of the strongly positive cells for AAV1, 5, 8 and 9 totally lacked
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Fig. 6. GABAergic expression of hrGFP driven by CaMKII and SynI promoters. (A) An AAV1/CaMKII-hrGFP injected sample was immunostained with PV antibody (red). (B–D)
High  power views of the dotted rectangle in panel A. (E–G) High power views of dotted rectangles in panels B–D, respectively. The arrowheads indicate hrGFP-positive PV
cells.  (H) An AAV1/SynI-hrGFP injected sample was  immunostained with PV antibody (red). (I–Q) High power views of the dotted rectangles in layers 2 (I–K), 4 (L–N) and
5  (O–Q) of panel A. The arrowheads indicate hrGFP-positive PV cells. Note high coincidence of hrGFP (green) and PV (red) signals. In layer 5 (O–Q), large pyramidal cells
( terpre
w
N
g
s
Findicated by arrows) were strongly positive for hrGFP and negative for PV. (For in
eb  version of this article.)euN signals and exhibited size and morphology characteristic of
lial cells (e.g., Fig. 3K). For AAV1, we observed some strong positive
ignals to be colocalized with NeuN signals (Fig. 1A, arrowhead).
or AAV5, 8 and 9, there were very few NeuN-positive cells withtation of the references to color in this ﬁgure legend, the reader is referred to thehrGFP expression. However, we observed relatively large hrGFP-
positive cells to exhibit very low level of NeuN signals, which are
likely to be neuronal cells with repressed NeuN signals (Fig. 2L and
M; see below for more analyses on cell toxicity). The “granular”
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Fig. 7. AAV serotypes injected into mouse barrel cortex. AAV constructs containing CMV, CaMKII, and SynI promoters driving hrGFP expression were packaged in AAV1, 2, 5,
8,  and 9 capsids and injected into the mouse barrel cortex. The low-magniﬁed images of representative sections are shown for each combination. These are merged views for
hrGFP  (green) and NeuN (red) signals. To aid visualization, the contrasts of images are adjusted. So that we can directly compare the signal intensities across serotypes, the
sections for the same promoters were immunostained simultaneously, imaged and contrast-adjusted in exactly the same conditions. (For interpretation of the references to
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ppearance of CMV  construct at low magniﬁcation is, therefore,
xplained by the sparseness of strongly positive cells, which are
ostly neuronal for AAV2 and glial for other serotypes.
We next examined the transduction proﬁles of CaMKII-hrGFP
onstruct. As expected, almost all of the hrGFP-positive cells
ere neurons, as judged by colocalization with NeuN signals
Fig. 3F–J). On the other hand, the ratio of hrGFP-positive cells
mong the NeuN positive cells appeared to be low for all the
erotypes at ﬁrst glance: some NeuN-positive cells expressed hrGFP
t high level and others at moderate level, but the majority of the
euN-positive cells were “as green as” the surrounding extracellu-
ar space (e.g., surrounded by circles in Fig. 3O and P). Although
uch images give the impression that most neurons are nega-
ive for hrGFP, we considered these cells to be hrGFP-positive for
he following reasons. First, these images are single optical sec-
ions of confocal microscopy. It is highly likely that the hrGFP
ignals are contained within the NeuN stained cell bodies. Sec-
nd, there exist hrGFP negative spots that are clearly darker than
he surrounding tissues. These spots are considered to be the true
rGFP-negative cells (e.g., Fig. 3N–Q, arrow). There are also hrGFP-
egative spots with no NeuN staining. These spots are probably
lias, because they have Hoechst-stained nuclear (data not shown).
hird, the texture of the staining suggests that there exist a cell bodysurrounded by extracellular space. With this criteria (see methods
for detail), over ∼70% of the neurons in layer 3 were transduced
by AAV/CaMKII-hrGFP in the core region of infection, regardless
of serotypes (Fig. 3R). This result was  supported by double in situ
hybridization with hrGFP and VGluT1 probes (data not shown). We
consider that the “extracellular space” actually consists of matrices
made of neuropils of transduced neurons.
To conclude, as far as the CaMKII promoter is used, the neuronal
transduction efﬁciency is not very different between the serotypes.
At the titer we used, the majority of the neurons in the core of injec-
tion were transduced, and a subpopulation of neurons expressed
the transgene at very high level.
3.4. Cell toxicity caused by CMV-promoter driven hrGFP
expression
We  showed in Fig. 3L and M that some neurons with high hrGFP
expression exhibited low level of NeuN signals. This observation
raised the possibility that high hrGFP expression may  repress NeuN
expression and have general toxic effect on neurons. This was  espe-
cially true for AAV5, 8 and 9, for which almost no NeuN-positive
cells exhibited strong hrGFP signals (Fig. 3D and E). The data shown
for CMV  promoter in Fig. 3 was  obtained from a marmoset that had
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Fig. 8. Glial and neuronal expression of transgene from AAV serotypes in mouse cortex. Mouse cortical sections were immunostained with anti-hrGFP (green) and anti-NeuN
a tion o
f reade
t
o
r
n
p
l
(
i
t
S
i
o
a
A
a
C
t
p
c
d
t
rntibody  (red) to differentiate neuronal and glial transduction. A single optical sec
rom  layer 5. (For interpretation of the references to color in this ﬁgure legend, the 
hree-week waiting period (Table 1). At this time point, we already
bserved heavy accumulation of glia-like cells in the transduced
egions for AAV8 (data not shown). Such glial accumulations were
ot observed for AAV1. However, when we extended the waiting
eriod for six weeks for AAV1 and 9, we observed almost complete
oss of NeuN signals and inﬁltration of glias into the infected area
Fig. 4C and D).
There is a possibility that the toxic effect is due to AAV infection
tself rather than high hrGFP expression. To address this ques-
ion, we examined the NeuN expression for CaMKII-hrGFP and
ynI-hrGFP constructs, which had six week waiting period after
nfection. As shown in Fig. 4E–H, we did not observe adverse effects
n NeuN expression for these constructs even after six weeks. We
lso did not observe accumulation of glia cells for AAV1-CaMKII,
AV1-SynI or AAV9-SynI constructs, although we observed glial
ccumulation in the vicinity of potential needle scar for AAV9-
aMKII construct (Fig. 4E–H). At higher magniﬁcation, we observed
hat NeuN expression is not necessarily downregulated in hrGFP-
ositive neurons for CamKII or SynI constructs (Fig. 4I and J). We
onclude that AAV infection at the current titer (2.5 × 109 GC/0.5 l)
oes not itself have toxic effects on neurons, although high-level
ransgene expression from the CMV  construct may  be toxic to neu-
ons.f confocal microscopy images are shown in each panel. These images were taken
r is referred to the web version of this article.)
3.5. Cell type preference of CaMKII and SynI promoters
In a previous study, CaMKII and SynI constructs in AAV1
serotype exhibited preferential expression in excitatory and
inhibitory neurons, respectively, in the mouse cortex at low dosage
(Nathanson et al., 2009). In Fig. 5, we compared the properties of
CaMKII and SynI promoters in side-by-side comparison. Fig. 5A
shows a ﬂuorescent image of the brain of marmoset #4, which
received injections of CaMKII and SynI constructs on left and
right hemispheres, respectively. As this overview image shows, the
intensity of SynI promoter construct appeared to be lower than
CaMKII constructs. At higher magniﬁcation, however, the ﬂuores-
cent intensity of these two constructs did not appear different so
much (Fig. 5B–E). One difference of the two promoters was that
CaMKII construct exhibited relatively uniform expression through-
out layers (Fig. 5B for AAV1, Fig. 5D for AAV9), as opposed to
layer 3 and 5-enriched expression of SynI construct (Fig. 5C for
AAV1, Fig. 5E for AAV9). The hrGFP expression from SynI construct
was prevalent in only a limited population outside layers 3 and 5
(Fig. 5F–I).
To conﬁrm the cell-type speciﬁc expression from these con-
structs, we tested the colocalization of hrGFP from CaMKII and SynI
constructs with parvalbumin (PV), which is the major GABAergic
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Fig. 9. AAV serotypes injected into the macaque cortex. (A–J) AAV constructs containing CMV  and CaMKII promoters driving hrGFP expression were packaged in AAV1, 2, 5,
8,  and 9 capsids and injected into the macaque cortex (V1). Each vector solution was injected at one site in each track. The low-magniﬁed images of representative sections
are  shown for each combination. To aid visualization, the contrasts of images are adjusted to enable direct comparison of the signal intensities across serotypes. The sections
for  the same promoters were simultaneously imaged and contrast-adjusted in exactly the same conditions. (K and L) The NeuN and hrGFP-NeuN merged views of the M1  at
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nhibitory neuron subtype marker. For the CaMKII construct, it was
bvious that many PV-negative neurons express hrGFP (Fig. 6B–D).
t the same time, the PV-positive neurons also expressed hrGFP
t high efﬁciency (Fig. 6E–G: arrowheads). For SynI construct, the
trongly positive cells outside layers 3 and 5 coincided surprisingly
ell with the PV-positive neurons (Fig. 6I–Q: arrowheads), sup-
orting the previous ﬁndings in the mouse cortex. On the other
and, large pyramidal cells in layers 3 and 5 exhibited very high
evel of hrGFP (Fig. 6O–Q: arrows).
.6. Transduction of mouse cortical cells by AAV serotypes
To compare the properties of AAV transduction between mar-
oset and mouse, we injected the same AAV preparations to the
arrel cortex of mouse brains and counterstained with NeuN anti-
ody. Figs. 7 and 8 shows the low and high-power views of the same
et of AAV injection, as that shown for marmoset in Figs. 1 and 3.
he overall feature of AAV transduction was similar between mouse
nd marmoset. First, AAV2 transduction area was smaller com-
ared with other serotypes (Fig. 7). Second, as in marmoset, theion of NeuN around the center of the injection site, which suggests cell loss. (M–Q)
aque M1 following injection of AAV1 constructs containing CMV  promoter. Further
ession) in P (hrGFP) and Q (merged), respectively. Scale bar in A, L and M shows
widespread transduction in layers 2 and 5 occurred in some injec-
tions for AAV1, 8 and 9. At higher magniﬁcation, we  could observe
the transduction efﬁciency at the cellular level. Similar to the mar-
moset case, transduction by CMV-hrGFP construct resulted in very
few NeuN-positive cells to exhibit hrGFP expression. One notable
difference between mouse and marmoset was  the morphology of
glia cells transduced by AAV. Whereas the marmoset glia cells
transduced by CMV-hrGFP exhibited conspicuous cell bodies and
processes that almost look like neurons and were often attached
to neuronal cells, the transduced mouse glia cells exhibited highly
branched morphology (Fig. 8C′–E′). These may  correspond to oligo-
dendrocyte and astroglia, respectively. CaMKII construct in mouse
cortex transduced neurons efﬁciently and looked quite similar to
the patterns in marmoset cortex.
3.7. Transduction of macaque cortical cells by AAV serotypesTo compare the properties of AAV transduction between
marmoset and macaque monkeys, we  injected the same AAV prepa-
rations to either the primary visual cortex (V1) or motor cortex (M1)
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aig. 10. Neuronal expression of transgene from AAV serotypes in macaque cortex. 
red)  antibodies to identify neuronal transduction. A single optical section of confoc
ar  in A shows 20 m.  (For interpretation of the references to color in this ﬁgure le
f macaque brains. Fig. 9A–J shows the low-power view of the cor-
ical tissue around the injection sites of each serotype either with
MV  (Fig. 9A–E) or with CaMKII (Fig. 9F–J) promoter. The over-
ll feature of AAV transduction was similar between the macaque
nd marmoset. AAV2 transduction area was weaker compared
ith other serotypes (Fig. 9B and G). However, the widespread
ransduction in layers 2 and 5 was not as obvious as that in the
ouse or marmoset. At higher magniﬁcation, we  could observe
he transduction efﬁciency at the cellular level. Similar to the mar-
oset, transduction by CMV-hrGFP construct was low (Fig. 9M–Q)
n NeuN-positive cells to exhibit hrGFP expression and tissue dam-
ge was commonly found 8 weeks after the injection (Fig. 9K and
). In contrast, CaMKII construct in the macaque cortex did not
uch cause damage and its transduction efﬁciency was higher than
he CMV  construct. The efﬁciency of hrGFP transduction in NeuN-
ositive cells was similar to that of the marmosets (Fig. 10; AAV1;
3.4%, AAV2; 67.6%, AAV8; 41.3%, AAV9; 70.3%).
. Discussion
Choosing the right serotype for transduction is a key step for
uccessful manipulation of cortical cells. For this purpose, we  per-
ormed a series of injections for AAV1, 2, 5, 8 and 9 serotypes
n marmoset, mouse and macaque cortex. There are many prece-
ents of reports that investigated the transduction properties of
arious AAV serotypes in the cerebral cortex (Cearley and Wolfe,
006; Nathanson et al., 2009; Masamizu et al., 2010, 2011; Hutson
t al., 2012; Aschauer et al., 2013; Wang et al., 2014). What is
ew in the current study is that we used neuron-speciﬁc CaMKII
romoter for systematic comparison of serotypes. Most of past
tudies, except a few (Nathanson et al., 2009; Holehonnur et al.,
014), used ubiquitous promoters, such as CMV  and CAG pro-
oters, for serotype evaluation. We  found that the use of CaMKII
romoter is advantageous in two respects. First, we were able to
xamine the efﬁciency of neuronal transduction without the inter-
erence of glial expression. Second, we observed potential toxicity
nd inﬂammation caused by the high-level transgene expression
or CMV-construct but not for CaMKII construct. By avoiding the
roblem of glial expression and toxicity, we reached the conclu-
ion that AAV1, 2, 5, 8 and 9 can all efﬁciently transduce neurons
n marmoset, mouse and macaque cerebral cortex. Among these
erotypes, AAV2 tended to spread smaller than other serotypes,
nd AAV5 expressed lower level of transgene than other serotypesque cortical sections were immunostained with anti-hrGFP (green) and anti-NeuN
croscopy images are shown in each panel. These images were taken from V1. Scale
the reader is referred to the web version of this article.)
(see Fig. 1). Other than that, the behavior of AAV1, 8 and 9 did not
differ signiﬁcantly, at least for the CaMKII construct.
One important observation that emerged from the current study
is that the expression levels of the transduced neurons are variable
and that many neurons with low transgene expression are buried
in the matrices of transgene-positive neuropils that ﬁll the space
between the cell bodies. This observation was made possible by the
use of CaMKII promoter and may  have been overlooked in past stud-
ies. What is the cause for variable expression level among neurons?
One possibility is the different activity of promoters in different cell
types. Nathanson et al. reported that SynI and CaMKII promoters in
AAV1 serotype exhibit higher transcription activity in inhibitory
and excitatory neurons, respectively, at low dosage (Nathanson
et al., 2009). Indeed, we found a tendency for higher expression
in parvalbumin-positive inhibitory neurons from SynI promoter
(Fig. 6). But we  also observed strong expression from the SynI con-
struct in large pyramidal cells of layers 3 and 5 (Fig. 5E). Compared
with SynI promoter, the CaMKII promoter exhibited more diffuse
pattern, which suggest uniform transduction of excitatory neurons.
But CaMKII construct also transduced inhibitory neurons (Fig. 6).
To conclude, CaMKII and SynI promoters exhibit somewhat differ-
ent cell type-speciﬁc activity. But they are active both in excitatory
and inhibitory neurons, and cannot explain the variability among
the transduced neurons.
Another possibility for different expression level is the differ-
ence in multiplicity of transduction. We  believe that over ∼70% of
the neurons are transduced by AAV in our conditions. But the mul-
tiplicity of viral infection could be different among neurons and
it may  lead to differential transgene expression. In the marmoset
cortex, we  observed generally high-level transgene expression in
large pyramidal cells in layers 3 and 5 (e.g., see Fig. 4). This ten-
dency was  most conspicuous for SynI promoter but was observed
regardless of promoters, including CMV  promoter. We  speculate
that large pyramidal cells may  allow more viral entries via their
widespread dendritic ﬁelds. In support of this idea, the sparse
but widespread transduction occurred in large pyramidal cells
of layer 5 well beyond the core region (Fig. 2J). Interestingly,
Nathanson et al. reported that excitatory/inhibitory preference
of SynI construct dramatically changes by the titer of the viral
solution (Nathanson et al., 2009). In addition, they also observed
preferential expression in layer 5 pyramidal cells (in addition to
GABAergic cells) in the mouse cortex from SynI promoter when
the viral titer is low. This observation is consistent with our idea
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hat multiplicity of infection affects the apparent cell type prefer-
nce.
We have shown here that viral spread is smaller for AAV2 than
ther serotypes, which is supported by many reports in various sys-
ems (Klein et al., 2006; Aschauer et al., 2013; Burger et al., 2004;
utson et al., 2012; McFarland et al., 2009; Taymans et al., 2007;
cFarland et al., 2009; Hutson et al., 2012). However, we  do not
ompletely understand why the injection of the same viral prepa-
ations led to variable results as we have shown in Fig. 2. For one
hing, technical difﬁculty of accurate injection (e.g., leak from the
ole, or clogging of the glass needle) may  have led to variability.
nother possible reason is that the different cellular and ﬁber archi-
ecture of the injected tissues may  have affected the dispersion of
he viral particles. In a previous study, the relative efﬁciency of
AV infection was different between striatum, hippocampus and
ortex of the mouse brain, which have very different cytoarchi-
ectures (Aschauer et al., 2013). It is possible that the areas with
ifferent laminar depths and ﬁbrous architecture may  exhibit dif-
erence in AAV spread. We  have also yet to clarify the parameters
hat led to unusually widespread transduction in the upper layer
n some injections, which could be useful for many experimental
pplications.
It is previously reported that high-level expression of GFP in sub-
tantia nigra neurons by AAV8 lead to cell death (Klein et al., 2006).
ur data also support the toxicity of high-level transgene expres-
ion (Fig. 4). We  suspect that one possible reason for very different
ell tropism of AAV8 reported in this and previous study (Masamizu
t al., 2010, 2011) may  stem from difference in the extent of cell
eath and inﬁltration of glial cells. In our experiment for CMV  con-
truct, we observed presence of glia-like cells in transduced areas
or AAV 5 and 8, even at three weeks of injection (data not shown).
e cannot deny the possibility that there exist some impurity that
an only be removed by column chromatographic puriﬁcation and
ead to inﬂammation (Klein et al., 2008). Alternatively, the chro-
atographic puriﬁcation may  distinguish two populations of AAV
articles that have differential afﬁnity to neurons and glias. Another
actor to be considered is the toxicity of the transgene itself. Wallace
t al. reported that high-level expression of hrGFP is more toxic than
GFP to muscle cells (Wallace et al., 2013). Thus, potential toxicity
f transgene needs to be considered carefully to choose serotype
nd promoters for experiment. In this context, the relatively low
evel expression of transgene from AAV5 may  have been advanta-
eous for long-term experiments encountered in primates (Diester
t al., 2011).
Finally, we comment on the comparison of species in serotype
roperties. To our knowledge, this is the ﬁrst report that directly
ested the transduction properties of the same viral preparations
n different species. In all the species, transduction of AAV2 was
ow, while that of AAV1, 5, 8 and 9 was similarly high. As far as
he CaMKII construct is concerned, we did not observe very big dif-
erences among mice, marmosets and macaque monkeys. As for
he CMV  promoter, AAV1 was more neuronal than glial in mice,
hereas it was predominantly glial in marmoset. In the macaque,
he AAV transduction was observed in both neuronal and glial cells.
AV5, 8 and 9 was glial in both mouse and marmoset, but the mor-
hology suggests that the former is astroglia, while the latter is
ligodendrocyte. Such species differences may  occur as combined
ffects of differences in cortical architecture (e.g., width of layers,
ensity of cellular components and/or axonal ﬁbers, etc.), ratio of
ell types (neuronal and glial subtypes), and promoter activity in
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